2025. A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded Study of Risankizumab Compared With Deucravacitinib for the Treatment of Adult Patients With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy: 16-Week Results From IMMpactful. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s631. DOI:https://doi.org/10.25251/h9van576.